IKZF3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1107988	0.76	15/20
SCHEMBL1107991	0.58	13/20
SCHEMBL1398096	0.56	12/20
SCHEMBL1107980	0.56	11/20
SCHEMBL1398095	0.52	11/20
SCHEMBL708995	0.51	10/20
SCHEMBL1097558	0.74	9/20
SCHEMBL705635	0.39	9/20
SCHEMBL868592	0.73	8/20
SCHEMBL707720	0.51	8/20
SCHEMBL710316	0.41	8/20
SCHEMBL1096542	0.65	7/20
SCHEMBL283372	0.64	7/20
SCHEMBL424062	0.61	7/20
SCHEMBL1107962	0.55	7/20
SCHEMBL707722	0.42	7/20
Avadomide (SCHEMBL282749)	1.00	6/20
Avadomide (SCHEMBL634577)	1.00	6/20
SCHEMBL677652	0.78	6/20
SCHEMBL476914	0.73	6/20

Clinical trials — most relevant to IKZF3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Latency in Pulmonary Tuberculosis	PHASE3	COMPLETED
Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC	PHASE2	UNKNOWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML	PHASE1/PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer	PHASE1	RECRUITING
Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein	PHASE1	COMPLETED
Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia	PHASE1	SUSPENDED
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients	PHASE1	COMPLETED
Can Gluten-free Diet Prevent the Destruction of Beta-cells During Remission?	EARLY_PHASE1	UNKNOWN
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy	nan	UNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients	nan	UNKNOWN
Immune Function and the Progression to T1D	nan	RECRUITING
Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies	nan	RECRUITING
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Molecular Disease Profile of Hematological Malignancies	nan	UNKNOWN
T Regulatory Cells in Hepatitis c Infected Patients	nan	COMPLETED
Natural History Study of GATA2 Deficiency and Related Disorders	nan	RECRUITING
Cytokine Regulation of Natural Killer Receptors in Inhibiting Activated T Cell Function	nan	UNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Immunophenotyping and Xist Gene in AML	nan	UNKNOWN
Triple Negative Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL	nan	RECRUITING
Umbilical Cord Blood Treatment for Refractory Immune Cytopenia	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a IKZF3 binder may also engage these)

Protein	Name	Similarity
A2VDW9	—	1.000	A2VDW9 →
P81183	—	0.999	P81183 →
O13089	—	0.998	O13089 →
IKZF1	DNA-binding protein Ikaros	0.998	landscape →
O42410	—	0.996	O42410 →
O08900	—	0.996	O08900 →
IKZF2	Zinc finger protein Helios	0.993	landscape →
Q5R9W9	—	0.992	Q5R9W9 →
P57682	—	0.992	P57682 →
Q9H5V7	—	0.992	Q9H5V7 →
O60315	—	0.992	O60315 →
P25932	—	0.992	P25932 →
Q6NRM0	—	0.992	Q6NRM0 →
Q9R0G7	—	0.992	Q9R0G7 →
Q9JJN2	—	0.991	Q9JJN2 →
Q6XDT4	—	0.991	Q6XDT4 →
Q6GNP2	—	0.991	Q6GNP2 →
Q03267	—	0.991	Q03267 →
A4IFJ6	—	0.991	A4IFJ6 →
B7ZRU9	—	0.990	B7ZRU9 →
A0JPB4	—	0.990	A0JPB4 →
Q86UP3	—	0.990	Q86UP3 →
Q5ZLR2	—	0.990	Q5ZLR2 →
Q9N5X6	—	0.990	Q9N5X6 →
O73590	—	0.990	O73590 →
Q8BU00	—	0.990	Q8BU00 →
P34303	—	0.989	P34303 →
Q753Y2	—	0.989	Q753Y2 →
Q6ZN30	—	0.989	Q6ZN30 →
Q03112	—	0.989	Q03112 →